TY - JOUR
T1 - A molecular case report
T2 - Functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma
AU - Kulesz-Martin, Molly
AU - Lagowski, James
AU - Olson, Susan
AU - Wortham, Aaron
AU - West, Toni
AU - Thomas, George
AU - Ryan, Christopher W.
AU - Tyner, Jeffrey W.
PY - 2013/2
Y1 - 2013/2
N2 - Current therapies for renal cell carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulation of VEGF. A subset of patients harbor primary-refractory disease, as in this case, where there was no evidence for loss of VHL or chromosome 3p. We evaluated molecular targeted agents in viable tumor cells cultured from a patient's clear cell renal cell carcinoma (RCC). Of 66 agents, only dasatinib, an inhibitor of Src tyrosine kinase, strongly reduced viability of the patient's cultured kidney tumor cells. Immunostaining of the original primary tumor revealed strong positivity for VHL and Src protein expression. Functional evaluation of a patient's tumor cells appears feasible in the setting of RCC.
AB - Current therapies for renal cell carcinoma favor vascular endothelial growth factor receptor (VEGF-R) tyrosine kinase (TK) inhibitors (TKIs). In theory, these are most applicable in tumors that have lost VHL-with subsequent stabilization of HIF and upregulation of VEGF. A subset of patients harbor primary-refractory disease, as in this case, where there was no evidence for loss of VHL or chromosome 3p. We evaluated molecular targeted agents in viable tumor cells cultured from a patient's clear cell renal cell carcinoma (RCC). Of 66 agents, only dasatinib, an inhibitor of Src tyrosine kinase, strongly reduced viability of the patient's cultured kidney tumor cells. Immunostaining of the original primary tumor revealed strong positivity for VHL and Src protein expression. Functional evaluation of a patient's tumor cells appears feasible in the setting of RCC.
KW - Molecular targeted therapy
KW - Renal cell carcinoma
KW - Tyrosine kinase
UR - http://www.scopus.com/inward/record.url?scp=84873439685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873439685&partnerID=8YFLogxK
U2 - 10.4161/cbt.22960
DO - 10.4161/cbt.22960
M3 - Article
C2 - 23192268
AN - SCOPUS:84873439685
SN - 1538-4047
VL - 14
SP - 95
EP - 99
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 2
ER -